
Orthofix International (OFIX) Stock Forecast & Price Target
Orthofix International (OFIX) Analyst Ratings
Bulls say
Orthofix Medical Inc. has demonstrated robust growth in its global spine segment, achieving a 14.2% increase in fiscal year 2024 driven by distribution expansion and deeper penetration in existing accounts. The company is projected to see its adjusted EBITDA margin increase significantly from 8.4% in 2024 to 13.5% by 2027, reflecting improved operational efficiency and profitability. Additionally, with sustainable top-line growth rates expected in the mid-to-upper single digits and a transition to positive free cash flow generation by the second half of 2025, Orthofix is positioned favorably in the market.
Bears say
Orthofix Medical Inc. is projected to experience net interest expenses ranging from $19 million to $20 million in FY/25, indicating ongoing financial burdens that could hinder profitability. Additionally, while the company is expected to maintain its investment in research and development dollars, this spending may decrease as a percentage of revenue, raising concerns about future growth and innovation potential. Lastly, despite a favorable macroeconomic environment for the spine and orthopedics market, the stock is trading near its 52-week lows, suggesting investor skepticism about the company's immediate outlook and performance.
This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.
Orthofix International (OFIX) Analyst Forecast & Price Prediction
Start investing in Orthofix International (OFIX)
Order type
Buy in
Order amount
Est. shares
0 shares